Drug intelligence / Profile preview

docetaxel + sodium cantharidinate

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of docetaxel and sodium cantharidinate. Docetaxel is a cytotoxic chemotherapy agent that works by disrupting microtubule function, while sodium cantharidinate is a semi-synthetic derivative of cantharidin extracted from Mylabris. Sodium cantharidinate restricts cell cycle progression from S phase to G/M phase, inhibiting cell proliferation and inducing apoptosis. This combination has been studied as a second-line treatment for advanced/metastatic non-small cell lung cancer (NSCLC) patients with wild-type or unknown EGFR status.

Targets

PP1 (Protein phosphatase 1)TUBB (Tubulin (alpha and beta subunits))PP2A (Protein phosphatase 2A)

Beyond the preview

Go deeper on docetaxel + sodium cantharidinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + sodium cantharidinate.

Explore the full profile